Filing Flows › CytomX Therapeutics (CTMX) › Q2 2026
CytomX Therapeutics (CTMX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
CytomX Therapeutics (CTMX) reported revenue of $1.4M for the second quarter 2026 (Q2 2026), -92% from a year earlier and -86% from the quarter before.
CytomX Therapeutics, Q2 2026: revenue $1.4M (-92% year over year), net loss $20.7M, operating cash flow −$18.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -86% | -92% |
| Operating profit | −$23.8M | — | — |
| Net earnings | −$20.7M | — | — |
| Operating cash flow | −$18.1M | — | — |
What changed
Revenue was $1.4M in Q2 2026, down 92% year over year and down 86% from the previous quarter.
Operating costs exceeded revenue by $23.8M, an operating margin of -1677.1%. Total costs grew 26% against a revenue fall of 92%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $20.7M, wider than the previous quarter's $18.2M loss.
Operating cash flow was −$18.1M. Non-cash charges added back $2.6M of share-based compensation.
Questions
What was CytomX Therapeutics' revenue in the second quarter 2026?
CytomX Therapeutics (CTMX) reported revenue of $1.4M for the second quarter 2026 (Q2 2026), -92% from a year earlier and -86% from the quarter before.